 SEATTLE, Aug. 02, 2021 GLOBE NEWSWIRE -- Icosavax, Inc. Nasdaq: ICVX, a biopharmaceutical company leveraging its innovative virus-like particle VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the closing of its initial public offering of 13,953,332 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,819,999 additional shares, at an initial public offering price of 15.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Icosavax, were 209.3 million. Icosavaxs common stock is listed on the Nasdaq Global Select Market under the ticker symbol ICVX. 